

Translation

Notice: This document is an excerpt translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Tokyo, August 21, 2023
Alfresa Holdings Corporation

Announcement of Bio-Industry Support Agreement with Miltenyi Biotec B.V. & Co. KG for the Purpose of Establishing Cell Processing Facilities That Support the Gene Cell Therapy Market

On July 21, 2023, Cell Resources Corporation,* a subsidiary of the Alfresa Group (head office: Chiyoda-ku, Tokyo; Representative Director & President: Kotaro Arita; hereinafter “Cell Resources”) formed the following bio-industry support agreement with Miltenyi Biotec B.V. & Co. KG (hereinafter, “Miltenyi Biotec”) for the purpose of supporting the design, construction, and operation of facilities and processes for cell culture automation in the gene cell therapy market.

1. Background and Targets of the Agreement

Under the 22–24 Mid-term Management Plan: Leap into the Future “An Evolving Healthcare Consortium,” the Alfresa Group has adopted the creation of new value as a Group management policy and aims to create total supply chain services for regenerative medicine products by utilizing the Group’s value chain based on the strengths of each business segment. Amid these circumstances, Cell Resources is responsible for providing domestic cellular raw materials (master cells) and manufacturing cell processing products, including autologous and allogeneic cells, as a regenerative medicine-related business.

Regenerative medicine has great potential to be a growing domain in healthcare. However, to develop as an industry, it is essential to reform manufacturing, such as by enhancing productivity and stabilizing quality. Additionally, current circumstances make it difficult to expand production flexibly because the cell culture manufacturing process takes place within a clean room environment, which involves a significant workload for employees. To resolve such issues and advance regenerative medicine as an industry, we formed a bio-industry support agreement with Miltenyi Biotec, the global front-runner in fully automated cell processing systems in the gene cell therapy market.

Cell Resources will take this agreement as an opportunity to advance the development of a business foundation that provides contract cell processing services with a high level of automation in the gene cell therapy market and build a system for providing contract cell processing of high-efficiency, high-quality regenerative medicine products, such as CAR T cells, by establishing cell processing facilities that focus on systems for automating cell processing.

2. About Miltenyi Biotec

Miltenyi Biotec is a vertically integrated company that was founded in Germany in 1989 and carries out the development, manufacture, and commercialization of life science research tools, medical devices, related consumable goods, and regenerative medicine products, such as CAR T cells. The privately held global business has over 4,700 employees at sites in over 29 countries around the world. With expertise in biological and medical science fields, including immunology, stem cell biology, neuroscience, and cancer research, Miltenyi Biotec has significant research and development capabilities in the biotechnology industry and provides comprehensive

scientific support, consulting, and expert training services for the development and expansion of commercial cell manufacturing processes. As a result of collaboration with Miltenyi Biotec, the company can quickly gain access to CliniMACS Cell Factory[®] with its automated end-to-end closed cell processing platform, CliniMACS[®] Prodigy Platform, and equipment for flow cytometry analysis in quality control, MACSQuant[®] Platform, through Miltenyi Biotec's newly launched cell processing facility consultation service.

Inquiries about Miltenyi Biotec

Homepage: <https://www.miltenyibiotec.com/>

E-mail address: macsjp@miltenyibiotec.com

TEL: 03-5646-8910

Yoichi Uda, Marketing Department, Miltenyi Biotec K.K.

3. Outlook

While the impact of this agreement on performance is expected to be minimal at the current time, we believe that it will contribute to enhancing the Group's corporate value in the medium to long term.

If matters arise in the future related to this agreement that need to be disclosed, we will inform the relevant parties in a timely manner.

Note: Cell Resources became a wholly owned subsidiary of Alfresa Holdings Corporation on June 16, 2023.

Photograph at Miltenyi Biotec



(From right to left)

1. Yoshihito Otsuki, Representative Director & President, Miltenyi Biotec K.K.
2. Dr. Boris Stoffel, Managing Director, Miltenyi Biotec B.V. & Co. KG
3. Kotaro Arita, Representative Director & President of Cell Resources
4. Yusuke Fukujin, Representative Director & Deputy President of Alfresa Holdings Corporation

About the Alfresa Group

The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to making its corporate philosophy, “we create and deliver a fresh life for all,” come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, and operating dispensing pharmacies. Alfresa Holdings Corporation (TSE:2784) reported its consolidated revenue of ¥2.6 trillion for the fiscal year ended March 31, 2023. For more information, please see: <https://www.alfresa.com/eng/>